GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

被引：0

作者：

Sehn, L. ^{[1
,2
]}

Chua, N. ^{[3
]}

Mayer, J. ^{[4
]}

Dueck, G. ^{[5
]}

Trneny, M. ^{[6
]}

Bouabdallah, K. ^{[7
]}

Fowler, N. ^{[8
]}

Delwail, V. ^{[9
]}

Press, O. ^{[10
]}

Salles, G. ^{[11
]}

Gribben, J. ^{[12
]}

Lennard, A. ^{[3
]}

Lugtenburg, P. ^{[13
]}

Franklin, N. ^{[14
]}

Wassner-Fritsch, E. ^{[15
]}

Fingerle-Rowson, G. ^{[15
]}

Cheson, B. ^{[16
]}

机构：

[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[4] Brno & Masaryk Univ, Univ Hosp, Brno, Czech Republic

[5] BC Canc Agcy, Kelowna, Kelowna, BC, Canada

[6] Charles Univ Prague, Gen Hosp, Prague, Czech Republic

[7] CHU Haut Leveque, Pessac, France

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Univ Hosp, INSERM, Poitiers, France

[10] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[11] Hosp Civils Lyon, Pierre Benite, France

[12] Queen Mary Univ London, Barts Canc Inst, London, England

[13] Erasmus MC Canc Inst, Rotterdam, Netherlands

[14] F Hoffmann La Roche Ltd, Welwyn Garden City, Herts, England

[15] F Hoffmann La Roche Ltd, Basel, Switzerland

[16] Georgetown Univ Hosp, Washington, DC 20007 USA

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB691

引用

页码：273 / 273

页数：1

共 50 条

[1] GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma
Sehn, Laurie Helen
Chua, Neil Sun
Mayer, Jiri
Dueck, Gregory Scott
Trneny, Marek
Bouabdallah, Kamal
Fowler, Nathan Hale
Delwail, Vincent
Press, Oliver W.
Salles, Gilles A.
Gribben, John G.
Lennard, Anne
Lugtenburg, Pieternella J.
Franklin, Natalie
Fritsch, Elisabeth Wassner
Fingerle-Rowson, Guenter
Cheson, Bruce D.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
[2] GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Sehn, Laurie Helen
Chua, Neil Sun
Mayer, Jiri
Dueck, Gregory Scott
Trnen, Marek
Bouabdallah, Kamal
Fowler, Nathan Hale
Delwail, Vincent
Press, Oliver W.
Salles, Gilles A.
Gribben, John G.
Lennard, Anne
Lugtenburg, Pieternella J.
Franklin, Natalie
Fritsch, Elisabeth Wassner
Fingerle-Rowson, Guenter
Cheson, Bruce D.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[3] Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma
Cheson, Bruce D.
Trask, Peter C.
Gribben, John
Dimier, Natalie
Kimby, Eva
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Fritsch, Elisabeth Wassner
Sehn, Laurie H.
BLOOD, 2015, 126 (23)
[4] Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study
Cheson, Bruce D.
Trneny, Marek
Bouabdallah, Kamal
Dueck, Gregory
Gribben, John
Lugtenburg, Pieternella J.
Press, Oliver
Salles, Gilles A.
Fingerle-Rowson, Gunter
Mattiello, Federico
Wassner-Fritsch, Elisabeth
Sehn, Laurie H.
BLOOD, 2016, 128 (22)
[5] Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study
Sehn, Laurie H.
Trneny, Marek
Bouabdallah, Kamal
Dueck, Gregory
Gribben, John G.
Lugtenburg, P. J.
Salles, Gilles A.
Knapp, Andrea
Nielsen, Tina G.
Liu, Wenxin
Cheson, Bruce D.
BLOOD, 2019, 134
[6] OBINUTUZUMAB PLUS BENDAMUSTINE VERSUS BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE GADOLIN STUDY
Trneny, M.
Bouabdallah, K.
Dueck, G.
Gribben, J.
Lugtenburg, P.
Press, O.
Salles, G.
Sehn, L.
Berge, C.
Fingerle-Rowson, G.
Wassner-Fritsch, E.
Cheson, B.
HAEMATOLOGICA, 2016, 101 : 155 - 156
[7] Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
Bruce D. Cheson
Peter C. Trask
John G. Gribben
Natalie Dimier
Eva Kimby
Pieternella J. Lugtenburg
Catherine Thieblemont
Elisabeth Wassner-Fritsch
Aino Launonen
Laurie H. Sehn
Annals of Hematology, 2017, 96 : 253 - 259
[8] Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
Cheson, Bruce D.
Trask, Peter C.
Gribben, John G.
Dimier, Natalie
Kimby, Eva
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wassner-Fritsch, Elisabeth
Launonen, Aino
Sehn, Laurie H.
ANNALS OF HEMATOLOGY, 2017, 96 (02) : 253 - 259
[9] Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma
Hamlin, Paul A.
LANCET ONCOLOGY, 2016, 17 (08): : 1023 - 1025
[10] Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
Cheson, Bruce D.
Chua, Neil
Mayer, Jiri
Dueck, Greg
Trneny, Marek
Bouabdallah, Kamal
Fowler, Nathan
Delwail, Vincent
Press, Oliver
Salles, Gilles
Gribben, John G.
Lennard, Anne
Lugtenburg, Pieternella J.
Fingerle-Rowson, Gunter
Mattiello, Federico
Knapp, Andrea
Sehn, Laurie H.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2259 - +

← 1 2 3 4 5 →